COSMOS Pharmaceutical Corporation

TSE:3349 Stock Report

Market Cap: JP¥536.0b

COSMOS Pharmaceutical Future Growth

Future criteria checks 2/6

COSMOS Pharmaceutical is forecast to grow earnings and revenue by 6.7% and 7% per annum respectively. EPS is expected to grow by 6.6% per annum. Return on equity is forecast to be 10.7% in 3 years.

Key information

6.7%

Earnings growth rate

6.6%

EPS growth rate

Consumer Retailing earnings growth12.2%
Revenue growth rate7.0%
Future return on equity10.7%
Analyst coverage

Good

Last updated15 Aug 2024

Recent future growth updates

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 17
COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

Aug 17
An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Aug 01
COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

Jun 28
Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Jun 10
We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 17
COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

Mar 16
Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

Feb 28
Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

Earnings and Revenue Growth Forecasts

TSE:3349 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
5/31/20271,205,80830,16710,83360,34510
5/31/20261,128,32227,7185,67156,79413
5/31/20251,043,56025,9453,92948,86312
5/31/2024964,98924,454-63555,175N/A
2/29/2024936,70624,871N/AN/AN/A
11/30/2023900,11124,08568154,534N/A
8/31/2023863,22823,824N/AN/AN/A
5/31/2023827,69723,7977,79854,434N/A
2/28/2023802,83122,983N/AN/AN/A
11/30/2022788,29223,209-3,65541,973N/A
8/31/2022772,12723,393N/AN/AN/A
5/31/2022755,41423,155-11,30332,194N/A
2/28/2022743,61222,030N/AN/AN/A
11/30/2021733,38725,329-535,596N/A
8/31/2021726,67225,909N/AN/AN/A
5/31/2021726,42427,1561,81127,875N/A
2/28/2021733,22328,777N/AN/AN/A
11/30/2020723,30925,73628,88250,935N/A
8/31/2020709,06423,876N/AN/AN/A
5/31/2020684,40321,43539,51365,461N/A
2/29/2020653,52720,217N/AN/AN/A
11/30/2019638,03418,95110,65338,209N/A
8/31/2019622,10319,349N/AN/AN/A
5/31/2019611,13719,1855,33934,379N/A
2/28/2019597,71518,966N/AN/AN/A
11/30/2018585,53618,8571,30230,947N/A
8/31/2018572,80717,880N/AN/AN/A
5/31/2018557,99917,6333,13532,586N/A
2/28/2018542,93617,510N/AN/AN/A
11/30/2017526,52317,313N/A35,488N/A
8/31/2017514,88018,239N/AN/AN/A
5/31/2017502,73218,215N/A36,938N/A
2/28/2017490,03715,812N/AN/AN/A
11/30/2016477,73914,981N/A34,300N/A
8/31/2016463,51713,679N/AN/AN/A
5/31/2016447,27312,435N/A30,986N/A
2/29/2016433,32812,738N/AN/AN/A
11/30/2015423,81712,474N/A22,426N/A
8/31/2015414,04612,350N/AN/AN/A
5/31/2015408,46611,694N/A19,454N/A
2/28/2015402,69010,671N/AN/AN/A
11/30/2014392,52710,286N/A26,260N/A
8/31/2014382,82310,193N/AN/AN/A
5/31/2014371,82510,600N/A25,962N/A
2/28/2014360,16210,366N/AN/AN/A
11/30/2013349,9669,975N/A17,627N/A
8/31/2013340,8439,549N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3349's forecast earnings growth (6.7% per year) is above the savings rate (0.3%).

Earnings vs Market: 3349's earnings (6.7% per year) are forecast to grow slower than the JP market (8.5% per year).

High Growth Earnings: 3349's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3349's revenue (7% per year) is forecast to grow faster than the JP market (4.2% per year).

High Growth Revenue: 3349's revenue (7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3349's Return on Equity is forecast to be low in 3 years time (10.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.